Nobuaki Nakano

Nobuaki Nakano

Auto-generated profile, based on publicly available information

Nobuaki Nakano

Department of Hematology, Imamura General Hospital, Kagoshima, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
YKYasunori Kogure
Yasunori Kogure
TKTakuro Kameda
Takuro Kameda
JKJunji Koya
Junji Koya
MYMakoto Yoshimitsu
Makoto Yoshimitsu
KNKisato Nosaka
Kisato Nosaka
KKKeisuke Kataoka
Keisuke Kataoka
Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform–specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3′-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell–like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.

17 August 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
YSYuma Sakamoto
Yuma Sakamoto
TITakashi Ishida
Takashi Ishida
AMAyako Masaki
Ayako Masaki
TMTakayuki Murase
Takayuki Murase
MTMorishige Takeshita
Morishige Takeshita
HIHiroshi Inagaki
Hiroshi Inagaki
Summary: Adult T‐cell leukaemia/lymphoma (ATL) patients have a poor prognosis. Here, we investigated the impact of TP53 gene mutations on prognosis of ATL treated in different ways. Among 177 patients, we identified 47 single nucleotide variants or insertion‐deletions (SNVs/indels) of the TP53 gene in 37 individuals. TP53 copy number variations (CNVs) were observed in 38 patients. Altogether, 67 of 177 patients harboured TP53 SNVs/indels or TP53 CNVs, and were categorized as having TP53 mutations. In the entire cohort, median survival of patients with and without TP53 mutations was 1·0 and 6·7 years respectively (P < 0·001). After allogeneic haematopoietic stem cell transplantation (HSCT), median survival of patients with (n = 16) and without (n = 29) TP53 mutations was 0·4 years and not reached respectively (P = 0·001). For patients receiving mogamulizumab without allogeneic HSCT, the median survival from the first dose of antibody in patients with TP53 mutations (n = 27) was only 0·9 years, but 5·1 years in those without (n = 42; P < 0·001). Thus, TP53 mutations are associated with unfavourable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.

1 October 2002 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
HWH. Wakamoto
H. Wakamoto
MOM. Ohta
M. Ohta
NNN. Nakano
N. Nakano
Hemiconvulsions-hemiplegia (HH) syndrome is an acquired condition in which hemiplegia develops after a preceding febrile unilateral status epilepticus in a previously healthy child. Although viral encephalitis or vascular diseases may be the underlying etiology, the pathogenesis remains unknown in the majority of cases. We measured both plasma and cerebrospinal fluid cytokine levels in a girl with HH syndrome, and found elevated plasma concentrations of soluble interleukin-2 receptor and tumor necrosis factor-α, and a slightly increased plasma level of interleukin-6. Furthermore, she had a high serum concentration of soluble E-selectin, which is a marker of inflammatory endothelial activation. These findings suggest that proinflammatory cytokine-induced cerebrovascular endothelial injury could play a role in the pathogenesis of HH syndrome.

22 September 2014 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
NNN Nakano
N Nakano
AKA Kubota
A Kubota
MTM Tokunaga
M Tokunaga
TIT Itoyama
T Itoyama
TMT Makino
T Makino
AUA Utsunomiya
A Utsunomiya
High incidence of CMV infection in adult T-cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation

31 August 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue
NNNobuaki Nakano
Nobuaki Nakano
SFShigeo Fuji
Shigeo Fuji
TETetsuya Eto
Tetsuya Eto
TKToshiro Kawakita
Toshiro Kawakita
ATATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

21 June 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YSYoshimitsu Shimomura
Yoshimitsu Shimomura
MHMasahiko Hara
Masahiko Hara
SHShigeki Hirabayashi
Shigeki Hirabayashi
TKTadakazu Kondo
Tadakazu Kondo
SMShohei Mizuno
Shohei Mizuno
MYMasamitsu Yanada
Masamitsu Yanada